

## **Prior Authorization Form**

PCSK9

This form must be completed by the prescriber or authority	orized personnel. INCOMPLETE FORMS WILL BE RETURNED
Member Information	
LAST NAME:	FIRST NAME:
ID NUMBER:	DATE OF BIRTH:
Prescriber Information	
LAST NAME:	FIRST NAME:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
Requested Medication	
Praluent Repatha	
Strength:	
Quantity: Directions:	
Clinical Criteria Documentation	
. What is the primary diagnosis?	ICD Code:
2. Indicate the request type 🗌 New Start 🗌 Renewal.	Date therapy was started:
3. Is the requested medication prescribed by or in consultation with	a specialist related to the patient's diagnosis?
I. Is the patient adherent to a low-fat diet and exercise regimen?	Yes No
5. Please list <u>ALL</u> medications the patient has tried and failed that re	late to this request.
Drug name:Strength:Outcome:	Dates tried:
5a.) If member is statin intolerant due to myalgia, provide creatin	ne kinase (CK) labs.
5. Has member been adherent to high-dose statin therapy for at least	
7. How will this medication be used?	Adjunct to statin therapy, diet and exercise
Please list ALL medications the patient will use in combination with	the requested medication for treatment of this diagnosis?
8. Please provide the following labs (Note: Medical records are requined in the second s	red, i.e. chart notes or labs)
Pretreated: Curre	ent values:

Pretreated:	Current values:							
LDL-C level: mg/dL Date:	LDL-C level: mg/dL Date:							
Total Cholesterol: g/dL Date:	Total Cholesterol: mg/dL Date:							

© 2018 All Rights Reserved.

Revision Date: 05/01/2018



## **Prior Authorization Form: PCSK9**

LAST NAME:								FIRST NAME:															
											_												
Additio	onal q	uesti	on fo	r <u>Clini</u>	ical at	<u>heros</u>	<u>clero</u>	tic ca	<u>rdiova</u>	<u>ascula</u>	ar dise	ease (/	<u>ASCVI</u>	<u>D)</u>									

1. Has the patient experienced one of the following cardiovascular events?

- Acute coronary syndrome History of myocardial infarction
- □ Stable or unstable angina □ Coronary or other arterial revascularization
- □ Stroke □ Transient ischemic attack
- Peripheral arterial disease presumed to be of atherosclerotic origin

Additional questions for Homozygous familial hypercholesterolemia (HoFH)

- **1.** Does the patient have a history of prior results of genetic testing indicating an LDL-receptor mutation, familial defective apo B-100, or a PCSK9 mutation? (*If YES, please attach supporting chart documentation*)
- 2. Does the patient have an untreated LDL-C > 500 mg/dL and triglycerides <300mg/dL and both parents with documented untreated TC >250mg/dL? (If YES, please attach lab report)

#### Additional questions for Heterozygous familial hypercholesterolemia (HeFH)

1. Does the patient have a history of prior results of genetic testing indicating an LDL-receptor mutation, familial defe	ctive Voc	🗌 No
apo B-100, or a PCSK9 mutation? (If YES, please attach supporting chart documentation)		

2. Has diagnosis been confirmed by genotyping or by using either the Simon Broome or Dutch Lipid Network Criteria?

If YES, please attach chart documentation.

#### Prescriber Signature (Required)

Date

1 Yes

No No

No

(By signature, the Physician confirms the above information is accurate and verifiable by patient records.)

# Fax This Form to: 1-800-424-7573

### Mail Requests to:

GlobalHealth, Inc. ATTN: Prior Authorizations 210 Park Avenue, Suite 2800 Oklahoma City, OK 73102 Phone: 1-800-424-1789